Cite
HARVARD Citation
Jacobs, K. et al. (2020). Early use of tocilizumab and lead-in dose to mitigate flotetuzumab associated infusion-related reaction/cytokine release reaction in patients with relapsed or refractory acute myeloid leukemia. Immuno-oncology insights. 1 (3), p. . [Online].